GLP-1 부작용 | Pulse

**질문:** GLP-1 부작용 **AI 분석 결과:** 관련 문헌은 있으나 질문에 답하기에는 근거가 불충분합니다. 아래 검색된 문헌을 직접 확인해보세요. **인용 문헌:** [1] Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. — The lancet. Diabetes & endocrinology (2025) https://pubmed.ncbi.nlm.nih.gov/40961952/ [2] Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. — Frontiers in endocrinology (2024) https://pubmed.ncbi.nlm.nih.gov/39114288/ [3] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. — The New England journal of medicine (2025) https://pubmed.ncbi.nlm.nih.gov/40934115/ [4] Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. — Nature reviews. Cardiology (2023) https://pubmed.ncbi.nlm.nih.gov/36977782/ [5] Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. — Cell metabolism (2018) https://pubmed.ncbi.nlm.nih.gov/29617641/